U.S. Tech Hardware Stock News

NYSE:CAH
NYSE:CAHHealthcare

Is Cardinal Health (CAH) Pricing Reflect Its Strong 1-Year Rally And DCF Estimate

If you are wondering whether Cardinal Health's current share price lines up with its underlying value, this article will walk you through what the numbers actually say. The stock recently closed at US$217.08, with returns of 5.5% year to date and 71.7% over the last year. The past month and week show more muted moves, with a 1.7% decline and 0.3% decline respectively, which can change how investors think about both upside and risk. Recent coverage of Cardinal Health has focused on its role...
NasdaqGS:DPZ
NasdaqGS:DPZHospitality

Domino's Governance Proposals Put Board Oversight And Valuation In Focus

Shareholders have submitted two governance proposals ahead of Domino's Pizza's April 2026 annual meeting. One proposal requests an independent board chair policy at Domino's Pizza, ticker NasdaqGS:DPZ. The second proposal seeks to require that directors who do not receive a majority vote be removed within a defined timeframe. Domino's management has recommended voting against both proposals, setting up a governance-focused debate for investors. For investors watching Domino's Pizza at a...
NasdaqGM:TRUP
NasdaqGM:TRUPInsurance

Is Trupanion’s (TRUP) HABRI Partnership Quietly Redefining Its Evidence-Based Pet Care Strategy?

Earlier this week, the Human Animal Bond Research Institute announced a new partnership with Trupanion to advance research and initiatives that strengthen the human–animal bond, with a particular focus on veterans and service dogs. This collaboration links HABRI’s research expertise with Trupanion’s pet insurance platform and veteran-support programs, potentially deepening the company’s role in evidence-based pet healthcare and service animal support. We’ll now examine how Trupanion’s HABRI...
NasdaqGM:SITM
NasdaqGM:SITMSemiconductor

What SiTime (SITM)'s Strong Quarter and Robust Book-to-Bill Ratio Means For Shareholders

In recent days, several research firms reiterated positive views on SiTime after it reported a strong quarter, citing broad-based strength across Communications, Enterprise, and Datacenter markets and solid demand trends. Analysts also pointed to a book-to-bill ratio above 1.5 as an important indicator of sustained customer orders for SiTime’s precision timing solutions. Next, we’ll examine how this stronger-than-expected demand picture and robust book-to-bill ratio may influence SiTime’s...
NasdaqCM:NKTR
NasdaqCM:NKTRPharmaceuticals

A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Momentum And Undervaluation Signals

Event driven snapshot of Nektar Therapeutics Nektar Therapeutics (NKTR) has attracted attention after recent share price moves, with the stock showing positive returns over the past week, month and past 3 months. That invites a closer look at its current profile. See our latest analysis for Nektar Therapeutics. At a share price of $73.25, Nektar Therapeutics combines short term share price momentum with very large 1 year total shareholder return and a strong multi year rebound, despite a weak...
NasdaqGS:ICUI
NasdaqGS:ICUIMedical Equipment

Assessing ICU Medical (ICUI) Valuation After A Stretch Of Weak Share Price Returns

ICU Medical stock: recent performance snapshot ICU Medical (ICUI) has drawn investor attention after a stretch of weak returns, with the share price showing declines over the past month, past 3 months, year to date, and the past year. Against that backdrop, the company’s latest reported revenue of US$2.23b and net income of US$732,000, alongside positive annual revenue and net income growth rates, give investors concrete figures to assess the current share price. See our latest analysis for...
NasdaqGM:TRVI
NasdaqGM:TRVIPharmaceuticals

Why Trevi Therapeutics (TRVI) Is Down 17.2% After Doubling Down On Parallel IPF Cough Trials - And What's Next

Earlier in March 2026, Trevi Therapeutics announced it had completed an End-of-Phase 2 meeting with the FDA and secured alignment to run two global, randomized Phase 3 trials of nalbuphine ER (Haduvio) for IPF-related chronic cough, with both studies using 54 mg twice-daily dosing and cough-frequency reduction as the primary endpoint. An interesting aspect is that Trevi plans to run two pivotal Phase 3 trials in parallel, even though the FDA indicated one could be sufficient, potentially...
OTCPK:MCEM
OTCPK:MCEMBasic Materials

Monarch Cement (OTCPK:MCEM) Net Margin Of 26% Tests Steady Compounder Narrative

Monarch Cement FY 2025 Earnings Snapshot Monarch Cement (MCEM) has wrapped up FY 2025 with fourth quarter revenue of about US$68.7 million and basic EPS of US$5.18, alongside net income excluding extra items of US$18.1 million. This gives investors a clear read on its recent operating performance. Over recent periods, the company has seen quarterly revenue move between US$38.7 million and US$80.0 million, while basic EPS ranged from US$0.72 to US$7.21. This offers a wide band of outcomes that...
NasdaqGS:RIVN
NasdaqGS:RIVNAuto

Is Rivian Automotive (RIVN) Now Attractively Priced After Recent Share Price Swings

If you are wondering whether Rivian Automotive's share price still makes sense after all the excitement and volatility, you are not alone. Rivian's stock closed at US$14.86 recently, with returns of a 3.3% decline over 7 days, a 16.2% decline over 30 days, a 23.4% decline year to date, but a 38.2% gain over the past year and 14.2% over three years. Recent headlines around Rivian have focused on its position in the electric vehicle space and how sentiment has shifted as investors reassess...
NYSE:CL
NYSE:CLHousehold Products

Does Colgate-Palmolive's (CL) New Board Voice and Dividend Bump Hint at a Shifting Capital Play?

Colgate-Palmolive recently added Christopher S. Boerner, Ph.D., Chair and CEO of Bristol-Myers Squibb, to its Board and modestly lifted its quarterly dividend from US$0.52 to US$0.53 per share, effective for the second quarter of 2026. The combination of fresh healthcare-focused board expertise and a higher annualized dividend of US$2.12 subtly reshapes how investors may view Colgate-Palmolive’s governance and capital return profile. Next, we’ll examine how the dividend increase interacts...
NYSE:PD
NYSE:PDSoftware

PagerDuty (PD) Valuation Check After First GAAP Profitability And Post Earnings Share Price Drop

PagerDuty (PD) has drawn investor attention after its latest earnings report, which combined first time GAAP profitability with cautious revenue guidance, a sharp share price drop, and a cluster of analyst rating changes. See our latest analysis for PagerDuty. PagerDuty’s latest earnings and AI product updates come after a tough stretch for shareholders, with a 90 day share price return of 44.29% decline and a 1 year total shareholder return of 61.53% decline. This points to fading momentum...
NYSE:ZIM
NYSE:ZIMShipping

Is It Too Late To Consider ZIM Integrated Shipping Services (ZIM) After Its 92% One-Year Surge?

If you are wondering whether ZIM Integrated Shipping Services at US$26.99 is still priced attractively after a strong run, the key question is how its current share price lines up with its underlying fundamentals. The stock has been volatile recently, with a 2.9% decline over the last 7 days, a 21.6% gain over the past month, a 23.2% return year to date, and a 91.7% return over the last year. This comes on top of a very large 3 year and 5 year gain of roughly 2.5x and just under 3x...
NYSE:SYK
NYSE:SYKMedical Equipment

Why Stryker (SYK) Is Down 7.6% After Major Global Cyberattack Disrupts Operations And Patient Platforms

In March 2026, Stryker disclosed a major cyberattack linked to the Iran-associated Handala group that disrupted its global Microsoft-based systems, wiping data on hundreds of thousands of devices and interrupting manufacturing, shipping and order processing across dozens of countries. The incident highlights how cybersecurity resilience has become a critical operational factor for large medtech companies whose connected platforms and hospital-facing digital ecosystems, such as Stryker’s new...
NYSE:ZTS
NYSE:ZTSPharmaceuticals

A Look At Zoetis (ZTS) Valuation As Investor Visibility And Fundamentals Draw Fresh Attention

Why Zoetis (ZTS) Is Back on Investor Radars Zoetis (ZTS) has been drawing fresh attention as management steps into multiple healthcare conferences and investor forums, while recent commentary has highlighted its role as a large pure-play animal health business. See our latest analysis for Zoetis. Despite Zoetis’s active presence at healthcare conferences and ongoing investor engagement, the share price has softened, with a 30 day share price return of 8.71% and a 1 year total shareholder...
NasdaqGS:SEDG
NasdaqGS:SEDGSemiconductor

Reassessing SolarEdge Technologies (SEDG) After 132% Rally And Mixed Valuation Signals

If you are wondering whether SolarEdge Technologies is attractively priced after a turbulent few years, you are not alone. This article focuses squarely on what the current share price might mean for long term investors. The stock sits at US$37.44, with returns of 12.1% over the last 7 days, 5.4% over 30 days, 19.4% year to date and 132.3% over the past year, while the 3 year and 5 year periods both show an 86.0% and 86.7% decline respectively. Recent coverage has centered on SolarEdge as a...
NYSE:WCN
NYSE:WCNCommercial Services

Should Waste Connections’ New 2036 Notes and EBITDA Outlook Reshape the Acquisition Story for WCN Investors?

In early March 2026, Waste Connections completed a US$600 million fixed-rate, callable senior unsecured notes offering, pricing the 4.80% 2036 bonds at 99.732% of face value with a small discount. This new long-dated bond issue, alongside the company’s recent earnings beat and 2026 revenue and EBITDA guidance, highlights how Waste Connections is pairing capital market access with operational execution. Now we’ll examine how Waste Connections’ better-than-expected quarterly results and 2026...
NYSE:MIR
NYSE:MIRElectronic

Why Mirion Technologies (MIR) Is Down 9.0% After Cutting 2026 EPS Guidance Below Expectations And Turning Cautious

In recent days, Mirion Technologies issued 2026 adjusted EPS guidance that came in below market expectations, following mixed fourth‑quarter results and cautious forward commentary. At the same time, institutional investors have highlighted Mirion’s entrenched presence in global nuclear and radiation monitoring markets and its growing backlog tied to digital transformation initiatives, underscoring a contrast between near‑term caution and longer‑term business strengths. We’ll now examine how...
NYSE:FOUR
NYSE:FOURDiversified Financial

Will Shift4 (FOUR) Management Shuffle Refine Its Global Expansion Story or Complicate Execution?

Shift4 Payments recently announced a series of leadership moves, including appointing Pier Francesco Nervini as President of Shift4 International, naming Timothy Goodwin as Chief Payments Officer, and reorganizing its accounting leadership following the planned departure of Chief Accounting Officer Jay Whalen. These changes align with Shift4’s push to scale its international operations and payment technology platform while maintaining continuity in its finance function. Next, we’ll examine...
NYSE:NPK
NYSE:NPKAerospace & Defense

National Presto Industries (NPK) Margin Compression Reinforces Bearish Narratives Despite Revenue Growth

National Presto Industries (NPK) just wrapped up FY 2025 with fourth quarter revenue of US$164 million and basic EPS of US$2.10, alongside trailing twelve month revenue of US$504 million and EPS of US$4.63 that sits against a 14.6% earnings growth figure and an 8.2% net margin for the year. The company has seen quarterly revenue move from US$134.7 million in Q4 2024 to US$164 million in Q4 2025, while EPS shifted from US$2.91 to US$2.10 over the same period, leaving investors to weigh the...
NasdaqGS:META
NasdaqGS:METAInteractive Media and Services

Meta Platforms (META) Valuation Check After Recent Share Price Pullback

Meta Platforms stock after recent pullback Meta Platforms (META) shares have eased in recent trading, with the stock showing declines over the past week, month and past 3 months. This has sharpened investor focus on current valuation and business fundamentals. See our latest analysis for Meta Platforms. At around US$613.71 per share, Meta’s recent pullback, including a 1-day share price return of 3.83% decline and a year to date share price return of 5.64% decline, contrasts with its 1-year...
NasdaqGM:CBFV
NasdaqGM:CBFVBanks

Net Interest Margin Stability At CB Financial Services (CBFV) Tests Bearish Profitability Narratives

CB Financial Services (CBFV) has wrapped up FY 2025 with fourth quarter revenue of US$15.2 million and EPS of US$0.94, capping off a year in which quarterly revenue moved from US$12.1 million in Q1 to US$15.2 million in Q4 while EPS ranged from US$0.37 to a temporary loss of US$1.14 in Q3 before rebounding. With forecasts pointing to faster revenue and earnings growth than the broader US market, the latest numbers put the spotlight on how sustainably the bank can rebuild its margins after a...
NasdaqCM:TALK
NasdaqCM:TALKHealthcare

Talkspace (TALK) Margin Turn To 3.4% Tests Bullish Earnings Narratives

Talkspace (NasdaqCM:TALK) closed out FY 2025 with Q4 revenue of US$63.0 million and basic EPS of US$0.03, alongside very large year over year earnings growth and a trailing twelve month net profit margin of 3.4% versus 0.6% a year earlier. The company has seen revenue move from US$48.7 million in Q4 2024 to US$63.0 million in Q4 2025, while basic EPS shifted from US$0.01 to US$0.03 over the same period, and trailing twelve month EPS reached US$0.05 on revenue of US$228.9 million. With...
NasdaqGS:CECO
NasdaqGS:CECOMachinery

CECO Environmental Ups 2026 Orders Outlook And Bets On Thermon Synergies

CECO Environmental (NasdaqGS:CECO) raised its 2026 orders outlook to more than $1.5b, which implies about 50% growth in bookings compared with the prior year. The company reported a record sales pipeline of over $6.5b, indicating a larger pool of identified opportunities. CECO announced an agreement to acquire Thermon Group Holdings for approximately $2.2b, with management highlighting expected double digit growth and meaningful cost synergies from the combination. For investors watching...
NYSE:CWK
NYSE:CWKReal Estate

A Look At Cushman & Wakefield (CWK) Valuation After Florida Expansion And Ongoing Share Price Weakness

Cushman & Wakefield (CWK) has expanded its Florida operations by adding NAI Southcoast brokerage and Johnson Schroth and Associates valuation teams, increasing its presence across the Space Coast and Treasure Coast commercial real estate markets. See our latest analysis for Cushman & Wakefield. Despite a steady stream of leasing wins, leadership changes and new mandates like the Florida expansion and recent deals in Texas, Virginia and Korea, Cushman & Wakefield’s share price has a year to...